Rome, Italy / Paris, France
September 1, 2026
Esserre Pharma, an Italian company active in the research and development of nutraceutical solutions, has signed a licensing agreement covering several European countries with Cooper Consumer Health, one of Europe’s leading consumer healthcare operators, for its patented Redulen™ Colesterolo technology.
Through this collaboration, the formulation has been further developed into a next-generation solution for cholesterol management.
As of October 1, 2026, Redulen Colesterolo will no longer be marketed in Italy. The next-generation formulation will be introduced and distributed by Cooper Consumer Health under the Armolipid™ Colesterolo Plus brand.
The partnership represents an important recognition of the research and innovation path developed by Esserre Pharma in the field of cardiovascular wellbeing. Cooper Consumer Health’s decision to license and further develop the formulation confirms the quality of the scientific and productdevelopment expertise built by Esserre.
For over ten years, Esserre Pharma has invested in developing nutraceutical solutions inspired by the principles of Mediterranean Nutrients for Life, with the aim of contributing to people's holistic wellbeing through innovative, sustainable and scientifically validated formulations.
“This agreement is a source of great satisfaction for us and a concrete acknowledgment of the work carried out over the years by the entire Esserre team, from R&D to marketing to our Nutra Advisors in the field. The partnership with Cooper Consumer Health confirms Esserre Pharma’s ability to develop high-value solutions capable of being recognized and valued by major international operators as well. At the same time, it allows us to strengthen our investment in future growth projects” said Amedeo Squillace, CEO of Esserre Pharma.
"We are pleased to announce this collaboration with Esserre Pharma, whose scientific and clinical expertise closely aligns with our ambition for developing high-quality, science-based healthcare products supported by clinical evidence" said Bart Meermans, CEO of Cooper Consumer Health. "By bringing this new generation, clinically studied formula into the Armolipid® portfolio, we are further strengthening one of our leading brands and expanding access to trusted nutritional options that support proactive cholesterol management as part of a healthy lifestyle."
The agreement is part of Esserre Pharma’s broader growth path, as the company continues to focus its strategy on research and on the development of the Mediterranean Nutrition Science platform, through which it will develop innovative products by studying the nutrients typical of the Mediterranean diet and region.
Esserre Pharma would like to thank all the healthcare professionals who, over the years, have chosen and recommended Redulen Colesterolo, contributing to the product’s growth, as well as all the team members whose expertise, passion and dedication made this milestone possible.
The partnership with Cooper Consumer Health is not a final destination, but a new milestone in Esserre Pharma’s journey: turning research, scientific knowledge and nutraceutical innovation into solutions recognized by the market and by the industry’s leading operators.
About Esserre Pharma
Esserre Pharma is an Italian company engaged in the research, development and marketing of parapharmaceutical products (food supplements, cosmetics, medical devices) in Italy and abroad. Its approach is built on the Mediterranean Nutrients for Life concept, which values the macro- and micronutrients typical of the Mediterranean diet and region, favoring a short and sustainable supply chain. Esserre owns the Mediterranean Nutrition Science™ technology platform, through which it develops the formulations marketed under the NutraMet™, Flomel™, Redulen™ and Improve™ brands. www.esserrepharma.com
For media inquiries, please contact:
marketing@esserrepharma.it
About Cooper Consumer Health
Cooper Consumer Health is a leading pure-play OTC consumer healthcare platform in Europe. The company develops, manufactures and distributes a broad portfolio of category-leading self care brands with high consumer awareness and loyalty, serving more than 100,000 pharmacies and
drugstores across Europe and beyond. https://www.cooperconsumerhealth.com/
For media inquiries, please contact:
Maxime Giordanengo
Head of Group Corporate Communication
maxime.giordanengo@cooperconsumerhealth.com
+33 6 19 79 51 04
